On Tuesday, Enliven Therapeutics Inc (NASDAQ: ELVN) opened higher 14.21% from the last session, before settling in for the closing price of $19.14. Price fluctuations for ELVN have ranged from $13.30 to $30.03 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -26.56% at the time writing. With a float of $32.21 million, this company’s outstanding shares have now reached $49.04 million.
In an organization with 62 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Enliven Therapeutics Inc (ELVN) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Enliven Therapeutics Inc is 34.36%, while institutional ownership is 73.72%. The most recent insider transaction that took place on Jun 03 ’25, was worth 143,550. Before that another transaction happened on Jun 03 ’25, when Company’s Officer proposed sale 7,500 for $19.14, making the entire transaction worth $143,550.
Enliven Therapeutics Inc (ELVN) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.4 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -26.56% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -21.18% during the next five years compared to 19.02% growth over the previous five years of trading.
Enliven Therapeutics Inc (NASDAQ: ELVN) Trading Performance Indicators
Check out the current performance indicators for Enliven Therapeutics Inc (ELVN). In the past quarter, the stock posted a quick ratio of 21.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.93, a number that is poised to hit -0.58 in the next quarter and is forecasted to reach -2.80 in one year’s time.
Technical Analysis of Enliven Therapeutics Inc (ELVN)
Let’s dig in a bit further. During the last 5-days, its volume was 0.45 million. That was better than the volume of 0.29 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 87.86%. Additionally, its Average True Range was 1.48.
During the past 100 days, Enliven Therapeutics Inc’s (ELVN) raw stochastic average was set at 78.32%, which indicates a significant decrease from 95.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 95.26% in the past 14 days, which was higher than the 71.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.40, while its 200-day Moving Average is $22.39. However, in the short run, Enliven Therapeutics Inc’s stock first resistance to watch stands at $23.06. Second resistance stands at $24.25. The third major resistance level sits at $26.36. If the price goes on to break the first support level at $19.76, it is likely to go to the next support level at $17.65. The third support level lies at $16.46 if the price breaches the second support level.
Enliven Therapeutics Inc (NASDAQ: ELVN) Key Stats
There are currently 49,069K shares outstanding in the company with a market cap of 1.07 billion. Presently, the company’s annual sales total 0 K according to its annual income of -89,020 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -28,540 K.
